Chronic Myeloid Leukemia - My Cancer Genome

Back to Diseases List

Associated Genetic Biomarkers

Overview

NCI Definition: A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival. [1]

Biomarker-Directed Therapies

View Therapies for Chronic Myeloid Leukemia

Of the biomarker-directed therapies for chronic myeloid leukemia, 4 are FDA-approved in at least one setting and 5 have NCCN guidelines in at least one setting [3].

Bosutinib +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

BCR-ABL1 Mutations in ALL AND CML (Bosutinib)

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NCCN), Relapse (NCCN)

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

BCR-ABL1 Mutations in ALL AND CML (Bosutinib)

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NCCN), Relapse (NCCN)

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NICE, BNF, SMC)

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NICE, BNF, SMC)

Disease is predicted to be resistant: -

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

ABL1 T315I, ABL1 V299L

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NCCN), Relapse (NCCN)

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

ABL1 T315I, ABL1 V299L

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NCCN), Relapse (NCCN)

Dasatinib +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (MCG), Relapse (FDA), Treatment Induction (FDA, NCCN)

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (MCG), Relapse (FDA), Treatment Induction (FDA, NCCN)

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

BCR-ABL1 Mutations in CML (Dasatinib)

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NCCN), Relapse (NCCN)

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

BCR-ABL1 Mutations in CML (Dasatinib)

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NCCN), Relapse (NCCN)

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NICE, BNF, SMC), Relapse (NICE, BNF, SMC), Treatment Induction (BNF, SMC)

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NICE, BNF, SMC), Relapse (NICE, BNF, SMC), Treatment Induction (BNF, SMC)

Disease is predicted to be resistant: -

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

BCR-ABL Res mutations in CML for Dasatinib (Therapy 970, 2795))

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NCCN), Relapse (NCCN)

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

BCR-ABL Res mutations in CML for Dasatinib (Therapy 970, 2795))

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NCCN), Relapse (NCCN)

Imatinib +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Treatment Induction (FDA, NCCN)

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Treatment Induction (FDA, NCCN)

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Treatment Induction (NICE, BNF, SMC)

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Treatment Induction (NICE, BNF, SMC)

Disease is predicted to be resistant: -

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

BCR-ABL1 Resistance Mutations in CML (Imatinib)

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NCCN)

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

BCR-ABL1 Resistance Mutations in CML (Imatinib)

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NCCN)

Nilotinib +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (FDA), Treatment Induction (FDA, NCCN)

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (FDA), Treatment Induction (FDA, NCCN)

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

BCR-ABL Sens Mutation in CML for Nilotinib (Therapy 971)

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (FDA, NCCN), Relapse (NCCN)

Note: Resistance or intolerant to prior therapy that included imatinib.

Biomarker Criteria: Sample must match all of the following: Sample must match one or more of the following: BCR-ABL Sens Mutation in CML for Nilotinib (Therapy 971) Sample must match all of the following: BCR-ABL1 Fusion	Clinical Setting(s): Refractory (FDA, NCCN), Relapse (NCCN)
	Note: Resistance or intolerant to prior therapy that included imatinib.

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NICE, BNF, SMC), Relapse (NICE, BNF, SMC), Treatment Induction (BNF)

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NICE, BNF, SMC), Relapse (NICE, BNF, SMC), Treatment Induction (BNF)

Disease is predicted to be resistant: -

Biomarker Criteria:

Sample must match all of the following:

Sample must match one or more of the following:

BCR-ABL Res Mutations in CML for Nilotinib (Therapy 983)

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NCCN), Relapse (NCCN)

Note: Applies if the cancer is resistant or intolerant to prior therapy that included imatinib.

Biomarker Criteria: Sample must match all of the following: Sample must match one or more of the following: BCR-ABL Res Mutations in CML for Nilotinib (Therapy 983) Sample must match all of the following: BCR-ABL1 Fusion	Clinical Setting(s): Refractory (NCCN), Relapse (NCCN)
	Note: Applies if the cancer is resistant or intolerant to prior therapy that included imatinib.

Ponatinib +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion, ABL1 T315I

Clinical Setting(s): Refractory (FDA, NCCN), Relapse (FDA, NCCN)

Note: Indicated for T315I-positive CML (chronic phase, accelerated phase, or blast phase).

Biomarker Criteria: Sample must match all of the following: BCR-ABL1 Fusion, ABL1 T315I	Clinical Setting(s): Refractory (FDA, NCCN), Relapse (FDA, NCCN)
	Note: Indicated for T315I-positive CML (chronic phase, accelerated phase, or blast phase).

Biomarker Criteria:

Sample must match one or more of the following:

Clinical Setting(s): Refractory (FDA, NCCN), Relapse (FDA, NCCN)

Note: Indicated for T315I-positive CML (chronic phase, accelerated phase, or blast phase).

Biomarker Criteria: Sample must match one or more of the following: ABL1 T315I	Clinical Setting(s): Refractory (FDA, NCCN), Relapse (FDA, NCCN)
	Note: Indicated for T315I-positive CML (chronic phase, accelerated phase, or blast phase).

Biomarker Criteria:

Sample must match all of the following:

BCR-ABL1 Fusion

Clinical Setting(s): Refractory (NICE, BNF, SMC), Relapse (BNF, SMC), Treatment Induction (BNF)

Note: Applies if multiple prior TKI treatment failed.

Biomarker Criteria: Sample must match all of the following: BCR-ABL1 Fusion	Clinical Setting(s): Refractory (NICE, BNF, SMC), Relapse (BNF, SMC), Treatment Induction (BNF)
	Note: Applies if multiple prior TKI treatment failed.

Clinical Trials

View Clinical Trials for Chronic Myeloid Leukemia

Significant Genes in Chronic Myeloid Leukemia

ABL1 +

ABL2 +

AFF1 +

ASXL1 +

ATM +

BCL2 +

BCL6 +

BCR +

BIRC3 +

CBFA2T3 +

CBFB +

CREBBP +

CRLF2 +

DEK +

DNMT3A +

ELL +

EPOR +

ETV6 +

FGFR1 +

FGFR2 +

FGFR3 +

FGFR4 +

FLT1 +

FLT3 +

GLIS2 +

HOXA9 +

HRAS +

IDH1 +

IGH +

IKZF1 +

IL7R +

JAK1 +

JAK2 +

JAK3 +

KAT6A +

KDM5A +

KIT +

KMT2A +

KRAS +

LYN +

MAF +

MAFB +

MECOM +

MLF1 +

MLLT1 +

MLLT10 +

MLLT3 +

MLLT4 +

MNX1 +

MYC +

MYH11 +

NPM1 +

NRAS +

NRIP3 +

NSD1 +

NTRK1 +

NTRK2 +

NTRK3 +

NUP214 +

NUP98 +

PBX1 +

PDGFRA +

PDGFRB +

PHF6 +

RET +

RPN1 +

RUNX1 +

RUNX1T1 +

SF3B1 +

SH2B3 +

TCF3 +

TET2 +

TP53 +

TYK2 +

WHSC1 +

WT1 +

Disease Details

Synonyms

BCR-ABL Positive Chronic Myelogenous Leukemia, CML, Chronic Granulocytic Leukemia, Bone marrow leukemia non-lymphocytic chronic myelocytic (CML), Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemias, CML - Chronic Myelogenous Leukemia, Hematopoeitic - Chronic Myelocytic Leukemia (CML), Chronic Myelogenous Leukemia, Chronic Myelocytic Leukemia

Parent(s)

Myeloproliferative Neoplasm

OncoTree Name

Chronic Myelogenous Leukemia

OncoTree Code

CML

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.